Related Experiment Videos
[Heparin-associated thrombocytopenia as a problem in heparin therapy]
S Schmidt1, A Lüdtke-Handjery, K H Lottermoser
1Abteilung für Chirurgie, Evangelisches Waldkrankenhaus Berlin-Spandau.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|September 1, 1993
Summary
Heparin-associated thrombocytopenia (HAT) can cause severe, fatal blood clots if not identified early. Regular platelet count monitoring during heparin therapy is vital for patient safety.
Area of Science:
- Clinical Medicine
- Hematology
- Pharmacology
Background:
- Heparin is widely used for thrombosis prophylaxis and treatment.
- Heparin-associated thrombocytopenia (HAT) is a rare but serious adverse effect of heparin therapy.
- Early recognition of HAT is crucial to prevent severe complications.
Observation:
- This report describes the clinical presentation of a typical case of HAT.
- The case highlights the potential for thrombo-embolic events in undiagnosed HAT.
- The patient's clinical course underscores the importance of vigilant monitoring.
Findings:
- HAT can manifest with a significant drop in platelet count.
- Thrombo-embolic complications are a major risk associated with HAT.
- Delayed diagnosis and management of HAT can lead to adverse outcomes, including death.
Implications:
- Increased clinical awareness and prompt diagnosis of HAT are essential.
- Routine monitoring of platelet counts in patients receiving heparin is recommended.
- Implementing standardized monitoring protocols can improve patient outcomes and reduce heparin-related morbidity and mortality.